Cytokinetics financials
WebCytokinetics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View CYTK financial statements in full. WebApr 13, 2024 · The projected fair value for Cytokinetics is US$38.04 based on 2 Stage Free Cash Flow to Equity. Cytokinetics' US$34.05 share price indicates it is trading at similar levels as its fair value estimate
Cytokinetics financials
Did you know?
WebCYTK Cytokinetics Inc. Annual Income Statement - WSJ Subscribe Sign In Cytokinetics Inc. CYTK (U.S.: Nasdaq) View All companies AT CLOSE 4:00 PM EDT 03/28/23 $34.98 … WebCytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the …
WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2024 at 10:00 … WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled ...
WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, ... Financials. Revenues for the three and twelve months ended December 31, 2024 were $2.0 million and $94.6 million ... WebApr 12, 2024 · Finally, Truist Financial assumed coverage on Cytokinetics in a report on Tuesday, December 20th. They issued a “buy” rating and a $60.00 price target for the company. One research analyst has ...
WebApr 2, 2024 · Financials In 2024, Cytokinetics reported revenues of $2.0 million for Q4 and $94.6 million for the full year, compared to $55.6 million and $70.4 million in the same …
WebMar 31, 2024 · April 10, 2024. Cytokinetics to Participate in the 22nd Annual Needham Virtual Healthcare Conference. SOUTH SAN FRANCISCO, Calif. , April 10, 2024 (GLOBE NEWSWIRE) -- … earn back defineWebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024(GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2024. Net loss for the fourth quarter was $137.4 millionor $1.45per share and the net loss for the year 2024 was $389.0 millionor $4.33per share. csv heartWebApr 11, 2024 · Cytokinetics, Incorporated (CYTK) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 33.36 -0.27 (-0.80%) At close: 04:00PM EDT 33.36 0.00 (0.00%) After hours: 04:11PM EDT Time... csvhelper ansiWebAug 5, 2024 · SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2024. ... Financials. Revenues for the ... csv heatmapWebMar 24, 2024 · CYTOKINETICS, INCORPORATED : Forcasts, revenue, earnings, analysts expectations, ratios for CYTOKINETICS, INCORPORATED Stock CYTK US23282W6057 csvhelper add new columnWebNov 4, 2024 · Inside Cytokinetics Inc's 10-Q Quarterly Report: Financial - Expense Highlight. Each of these adjustments is accounted for on a prospective basis in our liability calculation and resulted in a decline in our imputed interest rate and noncash interest expenses from 10% and $4.4 million in the second quarter of 2024 to 7.5% and $3.4 … earn back meaningWeb12 hours ago · In a report released yesterday, Madhu Kumar from Goldman Sachs maintained a Buy rating on Cytokinetics. The company’s shares closed last Thursday at … earn back period